GMAB / Genmab (GMAB), AbbVie Lymphoma Candidate Gets Orphan Drug Tag

Zai Lab Ltd.'s American depositary receipts ZLAB, +2.47% jumped 14% premarket on Tuesday after Seagen Inc. SGEN, +0.89% and Genmab A/S GMAB, +0.24% an more_horizontal

Genmab A/S , and Seagen Inc on Monday said that the Phase III trial of Tivdak in recurrent or metastatic cervical cancer patients on or after front-li more_horizontal

Genmab's stock is down 15% since late 2022 highs but the company and its partners continue to execute well. The approval and launch of Epkinly for the more_horizontal

Media Release COPENHAGEN, Denmark; August 28, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan van de Winkel, Ph.D. more_horizontal

Biotechnology is one of the most exciting and innovative sectors in the market, offering investors the potential for high returns coupled with groundb more_horizontal

Artificial intelligence (AI) has become an invaluable tool for investors seeking opportunities in the stock market. Its ability to analyze large amoun more_horizontal

Genmab's stock has seen negative price action despite the FDA approval of its drug, Epcoritamab, for relapsed/refractory diffuse large B-cell lymphoma more_horizontal

Media Release COPENHAGEN, Denmark; June 6, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano will partici more_horizontal